Jason Lettmann

Board Director

Director

Insider activity · 24 months1 buy4 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 1 saleMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 1 saleSept 25 · 1 buy · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 1 saleApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 1 saleSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (2 ops.)

€64k

▼ Sales (6 ops.)

€1.4M

Latest filing published 18 Aug 2026 for ALX Oncology Holdings INC, €3,716. Read the official filing

Filing timeline

BuySale

Jason Lettmann

Insider track record

Disclosed buys

Disclosed sells

Signal history

Closed purchases

Market purchases

Not enough history yet: 1 closed purchase, at least 2 are needed.

Purchases by company

ALX Oncology Holdings INC 2 purchases · last 18 Sept 2025

Since each purchase

ALX Oncology Holdings Inc
Filed 18 Sept 2025 · 395 days ago · €19k
+37.2%
Entry US$1.21 · Close at T+365 US$1.66

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Jason Lettmann: trading record in brief

This profile gathers the share dealings of Jason Lettmann in ALX Oncology Holdings Inc, where the filings describe the role as board member. Between 8 December 2021 and 17 August 2026, the trades on record add up to 12 filings.

Both buying and selling appear: 2 purchases worth €64k, against 6 sales worth €1.4M. Sales outweigh purchases by €1.3M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 4 share grants. 2026 to date brings no purchases and 2 sales.

The newest entry dates from 18 August 2026: an open-market sale of €3,716, in ALX Oncology Holdings Inc. The latest purchase dates back some time: it was published 395 days ago, on 18 September 2025. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.